Growing cases of brain tumours and nervous system tumours are fuelling demand for the glioma therapeutics across the globe. Technological advancement has reduced the difficulties in novel drug discovery process including TCGA and high throughput screening techniques. These developments have reduced time, energy and cost in the drug discovery process for the several type of diagnosis.
The global glioma therapeutics market size will grow by US$ 990 million by 2028 at a CAGR 9% in given forecast period.
Most of major players have failed in achieving desired results from the developed drugs and treatments from past few years due to the lack of approved therapies However, these providing the excellent opportunities for the players in participating new drug developments and introducing new therapeutics will boost glioma therapeutics market size. The high cost, side effects and long period of treatment may impact industry growth during the forecast time frame.
Global glioma therapeutics market is segmented based on the type as, glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma. On the basis of therapy, the global glioma therapeutics market is segregated as chemotherapy, targeted drug therapy, radiation therapy. Chemotherapy is expected to witness notable gains in the forecast years.
Global glioma therapeutics market report covers various regions including North America, Europe, Asia Pacific, and Rest of World. The regional glioma therapeutics market is further bifurcated for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Global glioma therapeutics market share consists of several players including Teva Pharmaceutical, Sun Pharmaceuticals, Emcure Pharmaceuticals, Pfizer Inc, Bristol-Myers Squibb Company, Arbor Pharmaceuticals, F. Hoffmann-La Roche Ltd, Amgen, AbbVie, Inc and Merck & Co.
The Glioma Therapeutics Market has been segmented as below:
Glioma Therapeutics Market, By Type
Glioma Therapeutics Market, By Therapy
Glioma Therapeutics Market, By Region
The report covers:
Report scope:
The global glioma therapeutics market report covers detailed study with the underlying influencing factors for the variations in the industry growth trends.
The report scope includes market analysis on regional as well as country level. The report also provides competitive landscape covering company market shares with detailed profiling for major revenue contributing companies.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Teva Pharmaceutical, Sun Pharmaceuticals, Emcure Pharmaceuticals, Pfizer Inc, Bristol-Myers Squibb Company, Arbor Pharmaceuticals, F. Hoffmann-La Roche Ltd, Amgen, AbbVie, Inc and Merck & Co.
Reasons to Buy this Report:
Customization:
Customized report as per the requirement can be offered with appropriate recommendations
Below are our new reports:
Breast Lesion Guidance Systems Market
Tissue Processing Systems Market
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Driver 1
4.2.2. Driver 2
4.2.3. Driver 3
4.3. Restraints
4.3.1. Restraint 1
4.3.2. Restraint 2
4.4. Opportunities
4.4.1. Opportunity 1
4.4.2. Opportunity 2
4.5. Challenges
4.5.1. Challenge 1
4.5.2. Challenge 2
5. Glioma Therapeutics Market, By Type
5.1. Key Points
5.2. Glioblastoma Multiforme
5.3. Anaplastic Astrocytoma
5.4. Anaplastic Oligodendroglioma
5.5. Anaplastic Oligoastrocytoma
6. Glioma Therapeutics Market, By Application
6.1. Key Points
6.2. Chemotherapy
6.3. Targeted Drug Therapy
6.4. Radiation Therapy
7. Competitive Landscape
7.1. Introduction
7.2. Recent Developments
7.2.1. Mergers & Acquisitions
7.2.2. New Product Developments
7.2.3. Portfolio/Production Capacity Expansions
7.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
7.2.5. Others
8. Company Profile
8.1. Teva Pharmaceutical
8.1.1. Company Overview
8.1.2. Product/Service Landscape
8.1.3. Financial Overview
8.1.4. Recent Developments
8.2. Sun Pharmaceuticals
8.2.1. Company Overview
8.2.2. Product/Service Landscape
8.2.3. Financial Overview
8.2.4. Recent Developments
8.3. Emcure Pharmaceuticals
8.3.1. Company Overview
8.3.2. Product/Service Landscape
8.3.3. Financial Overview
8.3.4. Recent Developments
8.4. Pfizer Inc
8.4.1. Company Overview
8.4.2. Product/Service Landscape
8.4.3. Financial Overview
8.4.4. Recent Developments
8.5. Bristol-Myers Squibb Company
8.5.1. Company Overview
8.5.2. Product/Service Landscape
8.5.3. Financial Overview
8.5.4. Recent Developments
8.6. Arbor Pharmaceuticals
8.6.1. Company Overview
8.6.2. Product/Service Landscape
8.6.3. Financial Overview
8.6.4. Recent Developments
8.7. F. Hoffmann-La Roche Ltd
8.7.1. Company Overview
8.7.2. Product/Service Landscape
8.7.3. Financial Overview
8.7.4. Recent Developments
8.8. Amgen
8.8.1. Company Overview
8.8.2. Product/Service Landscape
8.8.3. Financial Overview
8.8.4. Recent Developments
8.9. AbbVie, Inc
8.9.1. Company Overview
8.9.2. Product/Service Landscape
8.9.3. Financial Overview
8.9.4. Recent Developments
8.10. Merck & Co.
8.10.1. Company Overview
8.10.2. Product/Service Landscape
8.10.3. Financial Overview
8.10.4. Recent Developments
The Glioma Therapeutics Market has been segmented as below:
Glioma Therapeutics Market, By Type
Glioma Therapeutics Market, By Therapy
Glioma Therapeutics Market, By Region
